Drug prices & Part D
Medicare Insulin Costs Cut in Half Since 2020, KFF Report Finds
Per-prescription out-of-pocket insulin spending for Part D enrollees without low-income help fell from 54 dollars in 2020 to 25 dollars in 2024, driven by manufacturer pricing changes and a federal monthly cap that took effect in 2023.
By the Goodsurance editorial teamNovember 21, 2026
A KFF analysis of Medicare prescription drug claims finds that out-of-pocket spending per insulin prescription fell by more than half for Part D enrollees who do not receive low-income subsidies, dropping from 54 dollars in 2020 to 25 dollars in 2024. Total aggregate out-of-pocket insulin spending across all Part D enrollees declined from 971 million dollars in 2020 to 506 million dollars in 2024.
The decline reflects two waves of change. First, in 2021, the Part D Senior Savings Model began capping monthly copays for selected insulin products at 35 dollars in participating plans, and total out-of-pocket spending fell roughly 23 percent in that first year, to about 745 million dollars. Second, beginning in 2023, the Inflation Reduction Act required all Part D plans to cap monthly insulin cost-sharing at no more than 35 dollars, extending the protection to every covered insulin product across all plans regardless of which plan an enrollee chose.
Medicare insulin costs fell from 54 dollars to 25 dollars per prescription since 2020. Here is what drove the change.
Enrollees who qualify for Extra Help, the Part D Low-Income Subsidy, already had near-zero insulin cost-sharing before these changes. The largest gains in affordability went to the broader population of Part D enrollees who had faced the highest out-of-pocket exposure.
The analysis draws from prescription drug event claims in a 20 percent sample of Medicare beneficiaries held in the CMS Chronic Conditions Data Warehouse.
The findings arrive as Medicare open enrollment continues through December 7, 2026. For 2027, a new 2,400-dollar annual out-of-pocket cap on all Part D drug spending also takes effect. The 35-dollar monthly insulin cap continues to apply in every Part D plan.
In plain words
KFF is a group that studies health care costs. It looked at Medicare drug plan records from 2020 to 2024. People on Medicare without extra help now pay much less for insulin. Each prescription used to cost about 54 dollars out of pocket. By 2024, that fell to 25 dollars. Total insulin spending by all Medicare drug plan members dropped from 971 million dollars to 506 million dollars over those four years.
Two things helped. Starting in 2021, some Medicare drug plans began capping monthly insulin costs at 35 dollars. Then in 2023, a federal law made that 35-dollar monthly limit apply to every Medicare drug plan. People who already get extra help with their Medicare costs had been paying very little before these changes.
Open enrollment runs through December 7. For 2027, there is also a new cap on total yearly drug spending. The 35-dollar monthly insulin limit stays in place for all Medicare drug plans.
Understand the basics first
Source: KFF
Read at the source →